Metreleptin: First Global Approval

Overview

Journal Drugs

Specialty Pharmacology

Date 2013 Jun 7

PMID 23740412

Citations 34

Authors

Ken Chou

Caroline M Perry

Affiliations

Soon will be listed here.

Abstract

Metreleptin is an analogue of the human hormone leptin being developed by Amylin Pharmaceuticals (a subsidiary of Bristol-Myers Squibb) for the subcutaneous treatment of metabolic disorders including lipodystrophy. The compound is expected to improve insulin sensitivity, hypertriglyceridaemia and hyperglycaemia in patients with lipodystrophy who are unresponsive to conventional treatment. Metreleptin has been approved in Japan as a leptin therapy for the treatment of lipodystrophy. Amylin has also completed a submission for regulatory approval to the US FDA for metreleptin in the treatment of diabetes mellitus and/or hypertriglyceridaemia in patients with rare forms of lipodystrophy. Clinical development of the drug is also underway in the USA for the treatment of type 1 diabetes. Amgen was previously assessing the use of metreleptin as a treatment for amenorrhoea; however, it appears that development in this indication has been discontinued. This article summarizes the milestones in the development of metreleptin leading to this first approval for lipodystrophy.

Citing Articles

Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database.

Du H, Huang J, Wang Y, Wang C, Wang Y, Hou L BMC Gastroenterol. 2025; 25(1):148.

PMID: 40055604 PMC: 11887356. DOI: 10.1186/s12876-025-03732-2.

Advances in Oral Biomacromolecule Therapies for Metabolic Diseases.

Jiao Q, Huang Y, He J, Xu Y Pharmaceutics. 2025; 17(2).

PMID: 40006605 PMC: 11859201. DOI: 10.3390/pharmaceutics17020238.

Acquired Generalized Lipodystrophy as an Adverse Event of Combined Immune Checkpoint Inhibitor Therapy.

Kennedy R, Macrohon C, David M, Lee M, Salama A, Shariff A JCEM Case Rep. 2025; 3(3):luaf023.

PMID: 39935494 PMC: 11809239. DOI: 10.1210/jcemcr/luaf023.

Case report: First Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene.

Zhou Y, Zhang L, Ding Y, Zhai Y Front Genet. 2024; 15:1417613.

PMID: 39113684 PMC: 11303181. DOI: 10.3389/fgene.2024.1417613.

Correlation of Leptin in Patients With Type 2 Diabetes Mellitus.

Manglani K, Anika N, Patel D, Jhaveri S, Avanthika C, Sudan S Cureus. 2024; 16(4):e57667.

PMID: 38707092 PMC: 11070180. DOI: 10.7759/cureus.57667.

References

Sekhar R, Jahoor F, Iyer D, Guthikonda A, Paranilam J, Elhaj F . Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome. Metabolism. 2012; 61(10):1395-403. DOI: 10.1016/j.metabol.2012.03.013. View

McDuffie J, Riggs P, Calis K, Freedman R, Oral E, DePaoli A . Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab. 2004; 89(9):4258-63. PMC: 2266890. DOI: 10.1210/jc.2003-031868. View

Simha V, Subramanyam L, Szczepaniak L, Quittner C, Adams-Huet B, Snell P . Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab. 2011; 97(3):785-92. PMC: 3319219. DOI: 10.1210/jc.2011-2229. View

Arioglu Oral E, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P . Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002; 346(8):570-8. DOI: 10.1056/NEJMoa012437. View

Shetty G, Matarese G, Magkos F, Moon H, Liu X, Brennan A . Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol. 2011; 165(2):249-54. PMC: 3159386. DOI: 10.1530/EJE-11-0252. View

Garg A . Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011; 96(11):3313-25. PMC: 7673254. DOI: 10.1210/jc.2011-1159. View

Fujioka K, Patane J, Lubina J, Lau D . CSF leptin levels after exogenous administration of recombinant methionyl human leptin. JAMA. 1999; 282(16):1517-8. DOI: 10.1001/jama.282.16.1517. View

Chan J, Lutz K, Cochran E, Huang W, Peters Y, Weyer C . Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011; 17(6):922-32. PMC: 3498767. DOI: 10.4158/EP11229.OR. View

Sienkiewicz E, Magkos F, Aronis K, Brinkoetter M, Chamberland J, Chou S . Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism. 2011; 60(9):1211-21. DOI: 10.1016/j.metabol.2011.05.016. View

10.

Javor E, Cochran E, Musso C, Young J, DePaoli A, Gorden P . Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005; 54(7):1994-2002. DOI: 10.2337/diabetes.54.7.1994. View

11.

Ahren B, Baldwin R, Havel P . Pharmacokinetics of human leptin in mice and rhesus monkeys. Int J Obes Relat Metab Disord. 2000; 24(12):1579-85. DOI: 10.1038/sj.ijo.0801447. View

12.

Mantzoros C . W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?. Endocr Pract. 2010; 16(2):162-6. DOI: 10.4158/EP10038.ED. View

13.

Lee J, Chan J, Sourlas E, Raptopoulos V, Mantzoros C . Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab. 2006; 91(7):2605-11. DOI: 10.1210/jc.2005-1545. View

14.

Chan J, Wong S, Orlova C, Raciti P, Mantzoros C . Pharmacokinetics of recombinant methionyl human leptin after subcutaneous administration: variation of concentration-dependent parameters according to assay. J Clin Endocrinol Metab. 2007; 92(6):2307-11. DOI: 10.1210/jc.2006-2864. View

15.

Chong A, Lupsa B, Cochran E, Gorden P . Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2009; 53(1):27-35. DOI: 10.1007/s00125-009-1502-9. View

16.

Heymsfield S, Greenberg A, Fujioka K, Dixon R, Kushner R, Hunt T . Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999; 282(16):1568-75. DOI: 10.1001/jama.282.16.1568. View

17.

Chan J, Oral E . Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract. 2010; 16(2):310-23. DOI: 10.4158/EP09154.RA. View

18.

Chan J, Wong S, Mantzoros C . Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clin Pharmacokinet. 2008; 47(11):753-64. PMC: 2737404. DOI: 10.2165/00003088-200847110-00006. View

19.

Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N . Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2006; 92(2):532-41. DOI: 10.1210/jc.2006-1546. View

20.

Chou S, Chamberland J, Liu X, Matarese G, Gao C, Stefanakis R . Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A. 2011; 108(16):6585-90. PMC: 3080974. DOI: 10.1073/pnas.1015674108. View